Jump to main content
Jump to site search

Issue 43, 2015
Previous Article Next Article

Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells

Author affiliations

Abstract

Nanoparticles (NPs) for targeted therapy are required to have appropriate size, stability, drug loading and release profiles, and efficient targeting ligands. However, many of the existing NPs such as albumin, liposomes, polymers, gold NPs, etc. encounter size limit, toxicity and stability issues when loaded with drugs, fluorophores, and targeting ligands. Furthermore, antibodies are bulky and this can greatly affect the physicochemical properties of the NPs, whereas many small molecule-based targeting ligands lack specificity. Here, we report the utilization of biocompatible, biodegradable, small (∼30 nm) and stable iron oxide NPs (IONPs) for targeted delivery of paclitaxel (PTX) to HER2/neu positive breast cancer cells using an anti-HER2/neu peptide (AHNP) targeting ligand. We demonstrate the uniform size and high stability of these NPs in biological medium, their effective tumour targeting in live mice, as well as their efficient cellular targeting and selective killing in human HER2/neu-positive breast cancer cells.

Graphical abstract: Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells

Back to tab navigation

Supplementary files

Publication details

The article was received on 21 Jul 2015, accepted on 24 Sep 2015 and first published on 06 Oct 2015


Article type: Communication
DOI: 10.1039/C5NR04867B
Citation: Nanoscale, 2015,7, 18010-18014
  •   Request permissions

    Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells

    Q. Mu, F. M. Kievit, R. J. Kant, G. Lin, M. Jeon and M. Zhang, Nanoscale, 2015, 7, 18010
    DOI: 10.1039/C5NR04867B

Search articles by author

Spotlight

Advertisements